||Washington Duke Inn
||Saturday, Feb 16, 2013 12:00 PM
||To register scroll down.
The National Multiple Sclerosis Disease Management Consensus Statement recommends initiating a disease-modifying drug (DMD) as soon after definitive diagnosis as possible, and to also consider DMD therapy in select high-risk patients with a first attack. This push for earlier diagnosis and earlier initiation of DMD therapy has made MS management increasingly complex. This educational program will provide clinicians with the latest clinical evidence regarding earlier diagnosis and treatment of MS. It will also provide information on current and emerging DMD therapies to enable clinicians to rapidly select and initiate DMD therapy in MS, as well as exploring strategies to prevent gaps in DMD therapy and treatment discontinuations.
SUHAYL DHIB-JALBUT, MD
Professor and Chairman
Department of Neurology
UMDNJ-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ
AARON E. MILLER, MD
Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY
This activity is intended for neurologists and other health care providers actively involved in the care of patients with multiple sclerosis.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Explain the clinical implications of earlier diagnosis and therapy initiation in clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS)
- Select effective DMD therapies and initiate therapy earlier in the course of MS
- Provide patient-tailored therapy to optimize adherence, effectiveness, and patient outcomes
I. Diagnosis and Treatment Considerations in Early MS – Dr. Miller
II. Long-term Therapy Decision-making in MS – Dr. Dhib-Jalbut
- Evolving diagnostic criteria – CIS, RIS
- Earlier diagnosis, earlier DMD initiation, and clinical outcomes
- Current and emerging DMDs and initial therapy selection
- Addressing barriers to initiating and continuing therapy
- Biomarker and serology testing in MS
- Non-responders and alternative therapy selection
- Minimizing the risks of adverse events with prolonged therapy
- Tailoring therapies and dosages to optimize patient outcomes
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians – The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants – The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.
Nurse Practitioners – The American Academy of Nurse Practitioners accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME or a recognized state medical society. Nurse practitioners (and CNMs) may receive a maximum of 1.0 hours of Category I credit for completing this program.
For questions regarding CME credit, the post-test, or evaluation, please email email@example.com.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Suhayl Dhib-Jalbut, MD – Consultant: Bayer, Biogen, EMD Serono, Teva
Aaron E. Miller, MD – Consultant: Acorda, Biogen Idec, EMD Serono, GlaxoSmith Kline, Merck Serono, Nuron Biotech , Sanofi-Aventis, Teva Neuroscience; Consultant/Research Support: Acorda, Biogen Idec , Genentech, Genzyme, Novartis, Ono Pharmaceutical, Roche, Sanofi-Aventis
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Matthew Horn, MD; Bradley Pine; Blair St. Amand; Jay Katz, CCMEP; Dana Simpler, MD: Nothing to Disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
There is no fee for this program.
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided onsite upon receipt of the evaluation form. There are no fees associated with this program.
Jointly Sponsored By
This program is supported through an educational grant from Novartis and Teva CNS.
By clicking the Registration Button below you are agreeing that you have read and understood the CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.